Tadalafil Tablet, Film Coated
Product Images NDC 82804-041

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 82804-041). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-041-30 (Tadalafil 10 mg 1000s)

Tadalafil 10 mg tablets packaging label from Proficient Rx LP. Contains 30 yellow, almond-shaped tablets debossed with "T10." The label includes dosage strength, quantity, storage temperature (20°-25°C), manufacturer details (Umedica Laboratories Pvt. Ltd., India), and instructions that tablets should not be split and the entire dose should be taken. Also shows barcodes and lot/expiration placeholders.*

FDA Label Image

Tadalafil-figure-1 (Tadalafil Figure 1)

This image contains four line charts showing blood pressure differences over time between tadalafil and placebo. The charts display standing systolic and diastolic blood pressure and supine systolic and diastolic blood pressure, each plotted as the difference in mmHg over 0 to 96 hours. Error bars indicate variability at each time point.*

FDA Label Image

Tadalafil-figure-2 (Tadalafil Figure 2)

Two line graphs showing changes in systolic blood pressure (mmHg) over 24 hours after dosing. The top graph depicts standing systolic BP, comparing tadalafil 20 mg with doxazosin 8 mg and placebo with doxazosin 8 mg. The bottom graph shows supine systolic BP for the same treatments, both plotted against time post-dose in hours.*

FDA Label Image

Tadalafil-figure-3 (Tadalafil Figure 3)

A line graph depicting the changes in systolic blood pressure (mmHg) over 12 hours after administration of 20 mg tadalafil or placebo combined with 8 mg doxazosin. The graph includes four data sets showing blood pressure trends for tadalafil and placebo given at different times (08:00 and 20:00). The x-axis represents time after administration (hours), and the y-axis represents systolic blood pressure changes.*

FDA Label Image

Tadalafil-figure-4 (Tadalafil Figure 4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20 mg dose, single 5 mg dose, and once-daily 5 mg dose after 5 days. The graph includes error bars for variability at each time point with concentration levels highest for the single 20 mg dose and lower for the 5 mg doses.*

FDA Label Image

Tadalafil-figure-5 (Tadalafil Figure 5)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment for Tadalafil 5 mg tablets versus placebo. The x-axis shows the duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows the change from baseline in IPSS total score. The Tadalafil group shows a greater decrease in scores over time compared to placebo, with statistical significance indicated by P < 0.01.*

FDA Label Image

Tadalafil-figure-6 (Tadalafil Figure 6)

A line graph comparing change from baseline in IPSS Total Score over treatment duration (weeks) for Tadalafil Tablets 5 mg versus placebo. The graph shows Tadalafil with consistently greater decreases in score compared to placebo over 12 weeks of treatment, with statistical significance indicated at week 4 (P < 0.01).*

FDA Label Image

Tadalafil-figure-7 (Tadalafil Figure 7)

A line graph showing the least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows the LS mean change from baseline with values from 0 to -7. Tadalafil/Finasteride shows a greater negative change than Placebo/Finasteride at each time point, with statistical significance annotations (p<0.001 and p<0.05) noted.*

FDA Label Image

Tadalafil-figure-8 (Tadalafil Figure 8)

A line chart comparing change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil tablets 5 mg and placebo. The y-axis shows change from baseline, decreasing from 0 to -6, and the x-axis represents treatment duration in weeks (0 to 12). The graph shows a greater reduction in IPSS score with Tadalafil over time compared to placebo, with a statistically significant difference indicated at 12 weeks (p<0.01).*

FDA Label Image

Tadalafil-structure (Tadalafil Structure)

Chemical structure of tadalafil, showing its fused ring system with a benzodioxole moiety and characteristic methylated nitrogen and carbonyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.